Responsiveness of the Colombian Spanish version of the DLQI in patients with psoriasis who started treatment with biologic therapy.
ABSTRACT: Background: Psoriasis is a chronic disease that has been associated not only with loss of work productivity and absenteeism, but also with disability, depression, and suicidal ideation in affected patients. The aim of this study was to evaluate the responsiveness of the Colombian Spanish v...
- Autores:
-
Berbeo Velásquez, Yusmay Katerine
Tibaduiza García, Maria Fernanda
- Tipo de recurso:
- Tesis
- Fecha de publicación:
- 2022
- Institución:
- Universidad de Antioquia
- Repositorio:
- Repositorio UdeA
- Idioma:
- eng
- OAI Identifier:
- oai:bibliotecadigital.udea.edu.co:10495/29690
- Acceso en línea:
- https://hdl.handle.net/10495/29690
- Palabra clave:
- Arthritis psoriatic
Biological therapy
Quality of life
Artritis psoriásica
Terapia biológica
Calidad de vida
Responsiveness
Psoriasis
Dermatology life quality index (DLQI)
https://id.nlm.nih.gov/mesh/D015535
https://id.nlm.nih.gov/mesh/D001691
https://id.nlm.nih.gov/mesh/D011788
- Rights
- embargoedAccess
- License
- http://creativecommons.org/licenses/by-nc-sa/2.5/co/
Summary: | ABSTRACT: Background: Psoriasis is a chronic disease that has been associated not only with loss of work productivity and absenteeism, but also with disability, depression, and suicidal ideation in affected patients. The aim of this study was to evaluate the responsiveness of the Colombian Spanish version of DLQI instrument in patients with psoriasis who initiate treatment with biologic therapy. Methodology: Observational, descriptive, cross-sectional study based on retrospective data of patients with psoriasis treated in a referral center in the city of Medellin. Clinical and sociodemographic variables were collected, as well as patients' quality of life. The DLQI scale was applied before and 3 months after initiating biologic therapy. To assess the change between baseline and subsequent measurements, the effect size was determined with Cohen's d-test. Results: A total of 257 patients were included. Their mean age was 52.8 years. The main subtypes of psoriasis were chronic plaque psoriasis (88.3%), psoriatic arthropathy (33.5%). The subtypes with the highest baseline mean DLQI scores were pustular psoriasis (14.2), scalp psoriasis (6.81) and palmoplantar psoriasis (5.71). Most of the patients evaluated received treatment with anti-tumor necrosis factor drugs. Both the DLQI and PASI had lower mean scores throughout follow-up. The effect size obtained by Cohen's d-test, between baseline vs. first follow-up DLQI measurement after initiation of biologic therapy was mild for psoriasis classified as mild at baseline; however, the effect size was strong for patients who had severe psoriasis at their initial evaluation. Conclusions: The Colombian Spanish version of the Dermatological Quality of Life Index (DLQI) in patients with psoriasis has a low responsiveness even though the therapy implemented in these patients was effective. |
---|